Deirdre J Cohen

Summary

Affiliation: New York University School of Medicine
Country: USA

Publications

  1. doi request reprint Targeting the hedgehog pathway: role in cancer and clinical implications of its inhibition
    Deirdre J Cohen
    Division of GI Oncology, NYU Cancer Institute, 160 East 34th Street, New York, NY 10016, USA
    Hematol Oncol Clin North Am 26:565-88, viii. 2012
  2. doi request reprint An expert opinion on esophageal cancer therapy
    Deirdre J Cohen
    NYU Langone Medical Center, Division of Medical Oncology, New York University Cancer Institute, 160 East 34th Street, New York, NY 10016, USA
    Expert Opin Pharmacother 12:225-39. 2011
  3. doi request reprint Postoperative intraperitoneal 5-fluoro-2'-deoxyuridine added to chemoradiation in patients curatively resected (R0) for locally advanced gastric and gastroesophageal junction adenocarcinoma
    Deirdre J Cohen
    Division of Medical Oncology, New York University Cancer Center, NYU Medical Center, New York, NY, USA
    Ann Surg Oncol 19:478-85. 2012
  4. doi request reprint Treatment paradigms with epidermal growth factor receptor-targeted therapies in colorectal cancer
    Stacey Stein
    NYU Cancer Institute and Department of Medicine, New York University School of Medicine, NY, USA
    Clin Colorectal Cancer 9:S44-50. 2010
  5. ncbi request reprint Update on clinical data with regimens inhibiting angiogenesis and epidermal growth factor receptor for patients with newly diagnosed metastatic colorectal cancer
    Deirdre J Cohen
    Department of Medicine, NYU Clinical Cancer Center, New York, NY 10016, USA
    Clin Colorectal Cancer 7:S21-7. 2007
  6. pmc Rationale for combining biotherapy in the treatment of advanced colon cancer
    Deirdre J Cohen
    Department of Medicine Clinical, Pharmacology, New York University, Cancer Institute, New York, NY
    Gastrointest Cancer Res 2:145-51. 2008

Detail Information

Publications6

  1. doi request reprint Targeting the hedgehog pathway: role in cancer and clinical implications of its inhibition
    Deirdre J Cohen
    Division of GI Oncology, NYU Cancer Institute, 160 East 34th Street, New York, NY 10016, USA
    Hematol Oncol Clin North Am 26:565-88, viii. 2012
    ..This article summarizes the mechanism of Hh pathway signal transduction, discusses the models of pathway activation, reviews the clinical data using Hh inhibitors, and discusses challenges to the development of pathway inhibitors...
  2. doi request reprint An expert opinion on esophageal cancer therapy
    Deirdre J Cohen
    NYU Langone Medical Center, Division of Medical Oncology, New York University Cancer Institute, 160 East 34th Street, New York, NY 10016, USA
    Expert Opin Pharmacother 12:225-39. 2011
    ..Most patients present with regional or distant disease and, therefore, have a very poor prognosis...
  3. doi request reprint Postoperative intraperitoneal 5-fluoro-2'-deoxyuridine added to chemoradiation in patients curatively resected (R0) for locally advanced gastric and gastroesophageal junction adenocarcinoma
    Deirdre J Cohen
    Division of Medical Oncology, New York University Cancer Center, NYU Medical Center, New York, NY, USA
    Ann Surg Oncol 19:478-85. 2012
    ..However, locoregional recurrences remain high. Accordingly, we instituted this pilot/feasibility study, including intraperitoneal 5-fluoro-2'-deoxyuridine (IP FUDR) as part of the treatment...
  4. doi request reprint Treatment paradigms with epidermal growth factor receptor-targeted therapies in colorectal cancer
    Stacey Stein
    NYU Cancer Institute and Department of Medicine, New York University School of Medicine, NY, USA
    Clin Colorectal Cancer 9:S44-50. 2010
    ....
  5. ncbi request reprint Update on clinical data with regimens inhibiting angiogenesis and epidermal growth factor receptor for patients with newly diagnosed metastatic colorectal cancer
    Deirdre J Cohen
    Department of Medicine, NYU Clinical Cancer Center, New York, NY 10016, USA
    Clin Colorectal Cancer 7:S21-7. 2007
    ....
  6. pmc Rationale for combining biotherapy in the treatment of advanced colon cancer
    Deirdre J Cohen
    Department of Medicine Clinical, Pharmacology, New York University, Cancer Institute, New York, NY
    Gastrointest Cancer Res 2:145-51. 2008
    ..We review the various molecular targets of biologic therapy in colon cancer, discuss the rationale for their use as single agents and in combination, and present clinical evidence demonstrating their efficacy...